Literature DB >> 10222830

[Mechanisms of arbidole's immunomodulating action].

R G Glushkov, T A Gus'kova, L Iu Krylova, I S Nikolaeva.   

Abstract

The immunomodulating activity of arbidole was studied in cultured cells, animals, and human beings. Arbidole was shown to have effects on nonspecific defense factors, on its capacity to induce interferon and activate phagocytes in particular. Arbidole-treated patients with lower baseline immunity showed improvement in immunological parameters (in the counts of CD4 and CD8 lymphocytes, B lymphocytes, in the levels of serum immunoglobulins). Arbidol produces a high preventive and therapeutical effects in influenza A and B and other acute respiratory viral infections, prevents postinfluenza complications, reduces the incidence of exacerbations of chronic diseases in postinfluenza patients. In influenza, the therapeutical efficiency of the drug appears as decreases in intoxication, the severity of catarrhal syndrome, shorter fever and disease in general. Arbidole is beneficial for patients with second immunodeficiency, in those with recurrent herpes infection or chronic bronchitis. After arbidole treatment regimen, postoperative immunological parameters became normal in cardiac surgical patients, which suggests that the drug should be used in cardiac surgical care. The agent showed no side effects in any case.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10222830

Source DB:  PubMed          Journal:  Vestn Ross Akad Med Nauk        ISSN: 0869-6047


  10 in total

Review 1.  Advances in the possible treatment of COVID-19: A review.

Authors:  Pankaj Chibber; Syed Assim Haq; Irfan Ahmed; Nusrit Iqbal Andrabi; Gurdarshan Singh
Journal:  Eur J Pharmacol       Date:  2020-07-17       Impact factor: 4.432

2.  Efficacy of arbidol on lethal hantaan virus infections in suckling mice and in vitro.

Authors:  Hai-Ying Deng; Fan Luo; Li-Qiao Shi; Qiong Zhong; Ying-Juan Liu; Zhan-Qiu Yang
Journal:  Acta Pharmacol Sin       Date:  2009-06-08       Impact factor: 6.150

3.  Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection.

Authors:  Qiang Liu; Hai-rong Xiong; Li Lu; Yuan-yuan Liu; Fan Luo; Wei Hou; Zhan-qiu Yang
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150

Review 4.  Development of novel entry inhibitors targeting emerging viruses.

Authors:  Yanchen Zhou; Graham Simmons
Journal:  Expert Rev Anti Infect Ther       Date:  2012-10       Impact factor: 5.091

Review 5.  Arbidol as a broad-spectrum antiviral: an update.

Authors:  Julie Blaising; Stephen J Polyak; Eve-Isabelle Pécheur
Journal:  Antiviral Res       Date:  2014-04-24       Impact factor: 5.970

6.  Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.

Authors:  Xin Li; Yi Yang; Lancong Liu; Xuefeng Yang; Xiaobo Zhao; Yan Li; Yanyan Ge; Yuxin Shi; Ping Lv; Jianchu Zhang; Tao Bai; Hua Zhou; Pei Luo; Shilong Huang
Journal:  Pharmacol Res       Date:  2020-06-18       Impact factor: 7.658

7.  Data-driven multi-scale mathematical modeling of SARS-CoV-2 infection reveals heterogeneity among COVID-19 patients.

Authors:  Shun Wang; Mengqian Hao; Zishu Pan; Jinzhi Lei; Xiufen Zou
Journal:  PLoS Comput Biol       Date:  2021-11-24       Impact factor: 4.475

Review 8.  Review of trials currently testing treatment and prevention of COVID-19.

Authors:  P C Fragkou; D Belhadi; N Peiffer-Smadja; C D Moschopoulos; F-X Lescure; H Janocha; E Karofylakis; Y Yazdanpanah; F Mentré; C Skevaki; C Laouénan; S Tsiodras
Journal:  Clin Microbiol Infect       Date:  2020-05-23       Impact factor: 13.310

9.  Antioxidant Potential of Antiviral Drug Umifenovir.

Authors:  Elena V Proskurnina; Dmitry Yu Izmailov; Madina M Sozarukova; Tatiana A Zhuravleva; Irina A Leneva; Artem A Poromov
Journal:  Molecules       Date:  2020-03-30       Impact factor: 4.411

10.  Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers.

Authors:  Ming-Yan Liu; Shuang Wang; Wei-Fan Yao; Hui-zhe Wu; Sheng-Nan Meng; Min-Jie Wei
Journal:  Clin Ther       Date:  2009-04       Impact factor: 3.393

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.